Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, recently announced it was selected as a limited distribution partner for VYVGART
IntegriChain acquisition of Blue Fin Group expands its commercialization capabilities and strengthens the company’s market access expertise
PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).
AscellaHealth recently announced a comprehensive suite of Specialty Pharmacy (SP) services, including pre-commercialization, outsourced market access, wholesale, 3PL, limited distribution drug (LDD) fulfillment, and custom Patient Support and HUB Services
Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies
Optum® Frontier Therapies, a specialty pharmacy dedicated to people with rare disease, was founded to optimize every aspect of advanced therapeutics, from the point of prescribing to treatment and beyond
The FDA approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy
Optime Care recently announced the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care